Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue (BLUD, NEOG, ABAX, VIVO)

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue. The trailing-twelve-month revenue at Immucor Inc BLUD is $331.47 million. BLUD's operating margin for the same period is 39.64%. The trailing-twelve-month revenue at Neogen Corporation NEOG is $168.17 million. NEOG's ROE for the same period is 13.25%. The trailing-twelve-month revenue at ABAXIS Inc ABAX is $139.80 million. ABAX's operating margin for the same period is 15.61%. The trailing-twelve-month revenue at Meridian Bioscience Inc VIVO is $137.81 million. VIVO's PEG ratio is 1.96. Trading Ideas.